Devices and methods for modulating ADMA in blood

Patent metadata

Field	Value
Publication number	US-12533401-B2
Application number	US-202017642011-A
Country	US
Kind code	B2
Filing date	Sep 10, 2020
Priority date	Sep 13, 2019
Publication date	Jan 27, 2026
Grant date	Jan 27, 2026

Abstract

Compositions and methods are provided for metabolically degrading ADMA. In one embodiment a device is provided for reducing a patients ADMA levels in their blood wherein the device comprises a biologically active dimethylarginine dimethylaminohydrolase (DDAH) polypeptide covalently linked to a solid support. In one embodiment a method for reducing ADMA levels in a patients blood comprises the step of contacting the patients blood or a blood fraction with an immobilized biologically active DDAH polypeptide, wherein contact of the patients blood with said DDAH polypeptide results in degradation of ADMA present in the patients blood.

First claim

The invention claimed is:

1 . An ex vivo method for reducing ADMA in patients on dialysis, in ICU and disease states including kidney disease, acute kidney injury, sepsis, lung injury, preeclampsia, said method comprising the step of
contacting the patient's blood or plasma with a biologically active DDAH polypeptide covalently linked to a solid support of a therapeutic extracorporeal medical device, wherein the biologically active DDAH polypeptide comprises SEQ ID NO:13, wherein contact of the patient's blood or plasma with said DDAH polypeptide results in degradation of ADMA present in the patient's blood or plasma; and returning the contacted blood or plasma to the circulation of the patient.

2 . The method of claim 1 , wherein the solid support comprises a matrix of insoluble materials, wherein the biologically active DDAH polypeptide is covalently linked to the matrix.

3 . The method of claim 1 , wherein the solid support is in particulate form.

4 . The method of claim 1 , wherein the solid support is a monolithic strip, membrane, or sheet.

5 . The method of claim 1 , wherein the solid support comprises a plurality of biologically active DDAH polypeptides covalently linked to beads, wherein the beads are held in a column, wherein said column is configured for use as a component of a larger extracorporeal device that directs the flow of blood from a patient into contact with the plurality of biologically active DDAH polypeptides covalently linked on the solid support.

6 . The method of claim 1 , wherein the solid support is porous and the biologically active DDAH polypeptide is immobilized on the surface of the solid support throughout the external and internal spaces of said solid support.

7 . The method of claim 1 , wherein the therapeutic extracorporeal medical device is configured as a cartridge.

8 . The method of claim 1 , wherein the therapeutic extracorporeal medical device is integrated into a plasmapheresis system.

Assignees

• Univ Indiana Trustees

Inventors

• Singh Jaipal

Classifications

• A61P9/12

  Antihypertensives · CPC title

• A61M60/36

  for specific blood treatment; for specific therapy · CPC title

• A61M60/113

  in other functional devices, e.g. dialysers or heart-lung machines · CPC title

• A61M1/3486 Primary

  Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents · CPC title

• A61K47/6921

  the form being a particulate, a powder, an adsorbate, a bead or a sphere · CPC title